Isomorphic Labs, an AI-focused drug discovery and development company, has announced a $2.1 billion Series B funding round to advance its artificial intelligence-driven drug design platform and expand its global operations. The financing was led by Thrive Capital, with participation from existing investors Alphabet and GV, alongside new backers including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.
The company plans to use the capital to further develop and deploy its AI drug design engine, IsoDDE, while accelerating the progression of its therapeutic pipeline toward clinical application. Investment will also support hiring efforts across AI, engineering, drug discovery, and clinical development functions, enabling the company to scale its operations internationally.
“This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,” said Sir Demis Hassabis, founder and CEO of Isomorphic Labs. “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.”
Isomorphic Labs has developed a suite of proprietary AI models that form the foundation of IsoDDE, designed to operate across multiple therapeutic areas and drug modalities. The platform aims to improve predictive accuracy and streamline the transition from biological insight to viable drug candidates.
“This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,” said Max Jaderberg, president of Isomorphic Labs. “Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.”
The company’s progress has been supported by strategic collaborations with pharmaceutical partners including Novartis, Lilly, and Johnson & Johnson, which provide validation of its AI-driven approach.
“The application of AI in healthcare offers a profound opportunity. Isomorphic Labs has already made extraordinary progress in harnessing AI to accelerate drug discovery, and we are excited by this momentum and the early promise of the technology platform,” said Ruth Porat, president and chief investment officer of Alphabet and Google.
As the company continues to scale, Isomorphic Labs is positioning its AI platform as a core infrastructure for next-generation drug discovery, with the aim of improving speed, precision, and success rates across the development lifecycle.
Click here for the original news story.
